Amyloidogenic and non-amyloidogenic transthyretin variants interact differently with human cardiomyocytes: Insights into early events of non-fibrillar tissue damage

Bioscience Reports

Volumn 35, Issue , 2015, Pages

  Manral, Pallavi ^a   Reixach, Natàlia ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

Amyloidosis; Cardiomyocytes; Cytotoxicity; Protein misfolding; Proteotoxicity; Transthyretin

Indexed keywords

CASPASE 3; CASPASE 7; CHOLESTEROL; ISOLEUCINE; METHIONINE; PREALBUMIN; SUPEROXIDE; THREONINE; VALINE; AMYLOID;

ARTICLE; BINDING SITE; CELL INTERACTION; CONTROLLED STUDY; CYTOTOXICITY; ENZYME ACTIVATION; HEART MUSCLE CELL; HUMAN; HUMAN CELL; INTERNALIZATION; LYSOSOME; PROTEIN AGGREGATION; PROTEIN DEGRADATION; AMYLOIDOSIS; CARDIAC MUSCLE CELL; CELL LINE; GENETICS; METABOLISM; PATHOLOGY; POINT MUTATION; PROTEIN TRANSPORT; PROTEINOSIS;

AMYLOID; AMYLOIDOSIS; CASPASE 3; CASPASE 7; CELL LINE; HUMANS; MYOCYTES, CARDIAC; POINT MUTATION; PREALBUMIN; PROTEIN AGGREGATION, PATHOLOGICAL; PROTEIN TRANSPORT; PROTEOLYSIS; SUPEROXIDES;

EID: 84921673359     PISSN: 01448463     EISSN: 15734935     Source Type: Journal    
DOI: 10.1042/BSR20140155     Document Type: Article

References (56)

1. Buxbaum, J.N. (2008) In Rheumatology (Hochberg, M.C., Silman, A.J., Smolen, J.S., Weinblatt, M.E. and Weisman, M.H., eds), pp. 1671-1681, Elsevier, London
2. Buxbaum, J.N. and Reixach, N. (2009) Transthyretin: the servant of many masters. Cell Mol. Life Sci. 66, 3095-3101 CrossRef PubMed
3. Jacobson, D.R., Pastore, R.D., Yaghoubian, R., Kane, I., Gallo, G., Buck, F.S. and Buxbaum, J.N. (1997) Variant-sequence transthyretin (isoleucine 122) in late-onset cardiac amyloidosis in black Americans. N. Engl. J. Med. 336, 466-473 CrossRef PubMed
4. Buxbaum, J., Jacobson, D.R., Tagoe, C., Alexander, A., Kitzman, D.W., Greenberg, B., Thaneemit-Chen, S. and Lavori, P. (2006) Transthyretin V122I in African Americans with congestive heart failure. J. Am. Coll. Cardiol. 47, 1724-1725 CrossRef PubMed
5. Hammarstrom, P., Jiang, X., Hurshman, A.R., Powers, E.T. and Kelly, J.W. (2002) Sequence-dependent denaturation energetics: a major determinant in amyloid disease diversity. Proc. Natl. Acad. Sci. U. S. A 99, 16427-16432 CrossRef PubMed
6. Sekijima, Y., Wiseman, R.L., Matteson, J., Hammarstrom, P., Miller, S.R., Sawkar, A.R., Balch, W.E. and Kelly, J.W. (2005) The biological and chemical basis for tissue-selective amyloid disease. Cell 121, 73-85 CrossRef PubMed
7. Hurshman, A.R., White, J.T., Powers, E.T. and Kelly, J.W. (2004) Transthyretin aggregation under partially denaturing conditions is a downhill polymerization. Biochemistry 43, 7365-7381 CrossRef PubMed
8. Sousa, M.M., Cardoso, I., Fernandes, R., Guimaraes, A. and Saraiva, M.J. (2001) Deposition of transthyretin in early stages of familial amyloidotic polyneuropathy: evidence for toxicity of nonfibrillar aggregates. Am. J. Pathol. 159, 1993-2000 CrossRef PubMed
9. Sousa, M.M., Fernandes, R., Palha, J.A., Taboada, A., Vieira, P. and Saraiva, M.J. (2002) Evidence for early cytotoxic aggregates in transgenic mice for human transthyretin Leu55Pro. Am. J. Pathol. 161, 1935-1948 CrossRef PubMed
10. Teng, M.H., Yin, J.Y., Vidal, R., Ghiso, J., Kumar, A., Rabenou, R., Shah, A., Jacobson, D.R., Tagoe, C., Gallo, G. and Buxbaum, J. (2001) Amyloid and nonfibrillar deposits in mice transgenic for wild-type human transthyretin: a possible model for senile systemic amyloidosis. Lab. Invest. 81, 385-396 CrossRef PubMed
11. Buxbaum, J.N., Tagoe, C., Gallo, G., Walker, J.R., Kurian, S. and Salomon, D.R. (2012) Why are some amyloidoses systemic? Does hepatic 'chaperoning at a distance' prevent cardiac deposition in a transgenic model of human senile systemic (transthyretin) amyloidosis?. FASEB J. 26, 2283-2293 CrossRef PubMed
12. Reixach, N., Deechongkit, S., Jiang, X., Kelly, J.W. and Buxbaum, J.N. (2004) Tissue damage in the amyloidoses: Transthyretin monomers and non-native oligomers are the major cytotoxic species in tissue culture. Proc. Natl. Acad. Sci. U. S. A. 101, 2817-2822 CrossRef PubMed
13. Bourgault, S., Choi, S., Buxbaum, J.N., Kelly, J.W., Price, J.L. and Reixach, N. (2011) Mechanisms of transthyretin cardiomyocyte toxicity inhibition by resveratrol analogs. Biochem. Biophys. Res. Commun. 410, 707-713 CrossRef PubMed
14. Davidson, M.M., Nesti, C., Palenzuela, L., Walker, W.F., Hernandez, E., Protas, L., Hirano, M. and Isaac, N.D. (2005) Novel cell lines derived from adult human ventricular cardiomyocytes. J. Mol. Cell. Cardiol. 39, 133-147 CrossRef PubMed
15. Sorgjerd, K., Klingstedt, T., Lindgren, M., Kagedal, K. and Hammarstrom, P. (2008) Prefibrillar transthyretin oligomers and cold stored native tetrameric transthyretin are cytotoxic in cell culture. Biochem. Biophys. Res. Commun. 377, 1072-1078 CrossRef PubMed
16. Choi, S., Connelly, S., Reixach, N., Wilson, I.A. and Kelly, J.W. (2010) Chemoselective small molecules that covalently modify one lysine in a non-enzyme protein in plasma. Nat. Chem. Biol. 6, 133-139 CrossRef PubMed
17. Reixach, N., Foss, T.R., Santelli, E., Pascual, J., Kelly, J.W. and Buxbaum, J.N. (2007) Human-murine transthyretin heterotetramers are kinetically stable and non-amyloidogenic: A lesson in the generation of transgenic models of diseases involving oligomeric proteins. J. Biol. Chem. 283, 2098-2107 CrossRef PubMed
18. Zhao, L., Buxbaum, J.N. and Reixach, N. (2013) Age-Related Oxidative Modifications of Transthyretin Modulate Its Amyloidogenicity. Biochemistry 52, 1913-1926 CrossRef PubMed
19. Cheng, Y. and Prusoff, W.H. (1973) Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem. Pharmacol. 22, 3099-3108 CrossRef PubMed
20. Zhao, H., Joseph, J., Fales, H.M., Sokoloski, E.A., Levine, R.L., Vasquez-Vivar, J. and Kalyanaraman, B. (2005) Detection and characterization of the product of hydroethidine and intracellular superoxide by HPLC and limitations of fluorescence. Proc. Natl. Acad. Sci. U. S. A. 102, 5727-5732 CrossRef PubMed
21. Colon, W. and Kelly, J.W. (1992) Partial denaturation of transthyretin is sufficient for amyloid fibril formation in vitro. Biochemistry 31, 8654-8660 CrossRef PubMed
22. Choi, S., Reixach, N., Connelly, S., Johnson, S.M., Wilson, I.A. and Kelly, J.W. (2010) A substructure combination strategy to create potent and selective transthyretin kinetic stabilizers that prevent amyloidogenesis and cytotoxicity. J. Am. Chem. Soc. 132, 1359-1370 CrossRef PubMed
23. Liu, Y.W., Lukiyanchuk, V. and Schmid, S.L. (2011) Common membrane trafficking defects of disease-associated dynamin 2 mutations. Traffic. 12, 1620-1633 CrossRef PubMed
24. Schengrund, C.L. (2010) Lipid rafts: keys to neurodegeneration. Brain Res. Bull. 82, 7-17 CrossRef PubMed
25. Subasinghe, S., Unabia, S., Barrow, C.J., Mok, S.S., Aguilar, M.I. and Small, D.H. (2003) Cholesterol is necessary both for the toxic effect of Abeta peptides on vascular smooth muscle cells and for Abeta binding to vascular smooth muscle cell membranes. J. Neurochem. 84, 471-479 CrossRef PubMed
26. Eckert, G.P., Kirsch, C., Leutz, S., Wood, W.G. and Muller, W.E. (2003) Cholesterol modulates amyloid beta-peptide's membrane interactions. Pharmacopsychiatry 36, S136-S143 CrossRef PubMed
27. Adamski-Werner, S.L., Palaninathan, S.K., Sacchettini, J.C. and Kelly, J.W. (2004) Diflunisal analogues stabilize the native state of transthyretin. Potent inhibition of amyloidogenesis. J. Med. Chem. 47, 355-374 CrossRef PubMed
28. Johnson, S.M., Wiseman, R.L., Sekijima, Y., Green, N.S., Adamski-Werner, S.L. and Kelly, J.W. (2005) Native state kinetic stabilization as a strategy to ameliorate protein misfolding diseases: a focus on the transthyretin amyloidoses. Acc. Chem. Res. 38, 911-921 CrossRef PubMed
29. Klabunde, T., Petrassi, H.M., Oza, V.B., Raman, P., Kelly, J.W. and Sacchettini, J.C. (2000) Rational design of potent human transthyretin amyloid disease inhibitors. Nat. Struct. Biol. 7, 312-321 CrossRef PubMed
30. Reixach, N., Adamski-Werner, S.L., Kelly, J.W., Koziol, J. and Buxbaum, J.N. (2006) Cell based screening of inhibitors of transthyretin aggregation. Biochem. Biophys. Res. Commun. 348, 889-897 CrossRef PubMed
31. Alhamadsheh, M.M., Connelly, S., Cho, A., Reixach, N., Powers, E. T., Pan, D.W., Wilson, I.A., Kelly, J.W. and Graef, I.A. (2011) Potent kinetic stabilizers that prevent transthyretin-mediated cardiomyocyte proteotoxicity. Sci. Transl. Med. 3, 97ra81 CrossRef PubMed
32. Penchala, S.C., Connelly, S., Wang, Y., Park, M.S., Zhao, L., Baranczak, A., Rappley, I., Vogel, H., Liedtke, M., Witteles, R.M. et al. (2013) AG10 inhibits amyloidogenesis and cellular toxicity of the familial amyloid cardiomyopathy-associated V122I transthyretin. Proc. Natl. Acad. Sci. U. S. A. 110, 9992-9997 CrossRef PubMed
33. Lyras, L., Cairns, N.J., Jenner, A., Jenner, P. and Halliwell, B. (1997) An assessment of oxidative damage to proteins, lipids and DNA in brain from patients with Alzheimer's disease. J. Neurochem. 68, 2061-2069 CrossRef PubMed
34. Sayre, L.M., Smith, M.A. and Perry, G. (2001) Chemistry and biochemistry of oxidative stress in neurodegenerative disease. Curr. Med. Chem. 8, 721-738 CrossRef PubMed
35. Sousa, M.M., Du, Y.S., Fernandes, R., Guimaraes, A., Stern, D. and Saraiva, M.J. (2001) Familial amyloid polyneuropathy: receptor for advanced glycation end products-dependent triggering of neuronal inflammatory and apoptotic pathways. J. Neurosci. 21, 7576-7586 PubMed
36. Raha, S., McEachern, G.E., Myint, A.T. and Robinson, B.H. (2000) Superoxides from mitochondrial complex III: the role of manganese superoxide dismutase. Free Radic. Biol. Med. 29, 170-180 CrossRef PubMed
37. Haugland, R.P. (2002) Fluorescent Probes and Research Products, Molecular Probes, Eugene, Oregon
38. Andersson, K., Olofsson, A., Nielsen, E.H., Svehag, S.E. and Lundgren, E. (2002) Only amyloidogenic intermediates of transthyretin induce apoptosis. Biochem. Biophys. Res. Commun. 294, 309-314 CrossRef PubMed
39. Coelho, T., Carvalho, M., Saraiva, M., Alves, I., Almeida, M.R. and Costa, P.P. (1993) A strikingly benign evolution of FAP in an individual found to be a compound heterozygote for two TTR mutations: TTR MET 30 and TTR MET 119. J. Rheumatol. 20, 179
40. Jiang, X., Buxbaum, J.N. and Kelly, J.W. (2001) The V122I cardiomyopathy variant of transthyretin increases the velocity of rate-limiting tetramer dissociation, resulting in accelerated amyloidosis. Proc. Natl. Acad. Sci. U. S. A. 98, 14943-14948 CrossRef PubMed
41. Hammarstrom, P., Schneider, F. and Kelly, J.W. (2001) Trans-suppression of misfolding in an amyloid disease. Science 293, 2459-2462 CrossRef PubMed
42. Robinson, L.Z. and Reixach, N. (2014) Quantification of quaternary structure stability in aggregation-prone proteins under physiological conditions: the transthyretin case. Biochemistry, in the press
43. Divino, C.M. and Schussler, G.C. (1990) Receptor-mediated uptake and internalization of transthyretin. J. Biol. Chem. 265, 1425-1429 PubMed
44. Sousa, M.M. and Saraiva, M.J. (2001) Internalization of transthyretin. Evidence of a novel yet unidentified receptor-associated protein (RAP)-sensitive receptor. J. Biol. Chem. 276, 14420-14425 PubMed
45. Vieira, A.V., Sanders, E.J. and Schneider, W.J. (1995) Transport of serum transthyretin into chicken oocytes. A receptor-mediated mechanism. J. Biol. Chem. 270, 2952-2956 CrossRef PubMed
46. Kuchler-Bopp, S., Dietrich, J.B., Zaepfel, M. and Delaunoy, J.P. (2000) Receptor-mediated endocytosis of transthyretin by ependymoma cells. Brain Res. 870, 185-194 CrossRef PubMed
47. Divino, C.M. and Schussler, G.C. (1990) Transthyretin receptors on human astrocytoma cells. J. Clin. Endocrinol. Metab. 71, 1265-1268 CrossRef PubMed
48. Sousa, M.M., Norden, A.G., Jacobsen, C., Willnow, T.E., Christensen, E.I., Thakker, R.V., Verroust, P.J., Moestrup, S.K. and Saraiva, M.J. (2000) Evidence for the role of megalin in renal uptake of transthyretin. J. Biol. Chem. 275, 38176-38181 CrossRef PubMed
49. Hou, X., Parkington, H.C., Coleman, H.A., Mechler, A., Martin, L. L., Aguilar, M.I. and Small, D.H. (2007) Transthyretin oligomers induce calcium influx via voltage-gated calcium channels. J. Neurochem. 100, 446-457 CrossRef PubMed
50. Hou, X., Richardson, S.J., Aguilar, M.I. and Small, D.H. (2005) Binding of amyloidogenic transthyretin to the plasma membrane alters membrane fluidity and induces neurotoxicity. Biochemistry 44, 11618-11627 CrossRef PubMed
51. Incardona, J.P. and Eaton, S. (2000) Cholesterol in signal transduction. Curr. Opin. Cell Biol. 12, 193-203 CrossRef PubMed
52. Hou, X., Mechler, A., Martin, L.L., Aguilar, M.I. and Small, D.H. (2008) Cholesterol and anionic phospholipids increase the binding of amyloidogenic transthyretin to lipid membranes. Biochim. Biophys. Acta 1778, 198-205 CrossRef PubMed
53. Conner, S.D. and Schmid, S.L. (2003) Regulated portals of entry into the cell. Nature 422, 37-44 CrossRef PubMed
54. Zhao, H., Tuominen, E.K. and Kinnunen, P.K. (2004) Formation of amyloid fibers triggered by phosphatidylserine-containing membranes. Biochemistry 43, 10302-10307 CrossRef PubMed
55. Stock, C., Mueller, M., Kraehling, H., Mally, S., Noel, J., Eder, C. and Schwab, A. (2007) pH nanoenvironment at the surface of single melanoma cells. Cell Physiol. Biochem. 20, 679-686 CrossRef PubMed
56. Maouyo, D., Chu, S. and Montrose, M.H. (2000) pH heterogeneity at intracellular and extracellular plasma membrane sites in HT29-C1 cell monolayers. Am. J. Physiol. Cell Physiol. 278, C973-C981 PubMed